Apixaban Adoption Surges: Examining the Role of Novel Oral Anticoagulants in Thromboembolic Disorder Management
The introduction of Novel Oral Anticoagulants, or NOACs, marked a critical turning point in the management of thromboembolic disorders, conditions that range from deep vein thrombosis (DVT) and pulmonary embolism (PE) to the necessary prevention of stroke in patients with atrial fibrillation. Apixaban, as a leading Factor Xa inhibitor within this class, has driven significant adoption rates...
0 Kommentare 0 Geteilt 233 Ansichten 0 Bewertungen